Clean Science & Technology Ltd. share price target

Clean Science (CLEAN) reported a muted operating performance with an EBITDA of INR964m, down 3% YoY, while its gross margin dipped to 60.9% (from 65.5% in 1QFY26).

Clean Science and Technology (Clean) reported results which were above our expectations. Standalone revenue declined by 20% YoY which was majorly owing to lower offtake of established products, pricing pressure and loss of a Chinese customer for the 4-MAP product. Sharp decline in end product pricing amid high Chinese competitive intensity have impacted realisations in FY26. Market conditions have remained very challenging amid muted demand, pricing and tariff pressures. HALS exhibited healthy performance in FY26 with revenue growth of 83% YoY which mitigated the weakness in the standalone...

Clean Science and Technology (Clean) reported results which were much below our expectations. Volumes declined by 19% YoY leading to a 20% decline in standalone revenues. The decline in revenues was on account of drop in sales volumes of established products. This was owing to sharp decline in end product pricing amid high Chinese competitive intensity. Market conditions remained very challenging amid muted demand, pricing and tariff pressures. Chinese led competition has led to sharp downward pressure on Hydroquione (HQ) and Monomethyl Ether of Hydroquinone (MEHQ) prices impacting profitability. We...

Clean Science and Technology (Clean) reported results which were below our expectations. Volumes declined by almost 6% YoY leading to a ~7% decline in standalone revenues. The decline in revenues was owing to drop in sales volumes of established products. This was owing to sharp decline in end product pricing amid high Chinese competitive intensity. End markets of these products for certain customers are also seeing lower demand visibility. The management mentioned that one of the prominent FMCG Chinese customer could also have backward integrated which would mean permanent loss of volumes. However,...

Clean Science’s (CST) performance was impacted from a dip in volumes owing to demand headwinds and a Chinese customer backward integrating.

Clean Science and Technology (Clean) reported results which were in line with our expectations. The management stated that the growth is majorly led by volumes as realisations are steady. Favourable product mix led to better margin delivery at 41% as established products like MEHQ/BHA saw better growth while products with lesser salience like DCC, TBHQ and others saw weaker growth. Sales volume for HALS stood at 580 tons with total sales of Rs 240 mn in Q1FY26.The management maintained the target of 4500 tons and sales of Rs 2.1 bn for HALS in FY26 which will be driven through introduction of more...

Clean Science’s (CST) EBITDA grew only 5.5% YoY despite tailwinds of lower input prices, and HALS offtake. Its established products revenue has grown 8% YoY, while lower sales were due to weak demand for new products.

HALS volume reached 580tn in Q1FY26, sales volume guidance of 4,500tn for FY26 intact, current utilization at 22% Clean Science and Technology (CLEAN) reported revenue of Rs2.4bn in Q1FY26, marking an 8.4% YoY increase but a 7.9% QoQ decline. The sequential dip in topline was due to lower sales of newer products such as DCC and TBHQ. The Pharma & Agro Intermediates segment witnessed the sharpest decline, with revenue down 32% QoQ. Volume for the company's established products...

reflecting a 15.9% YoY increase and a 9.5% QoQ growth. The top-line expansion of HALS rose significantly to 1,900tn in FY25 from 600tn in FY24, with a blended realization of Rs425/kg. Management has guided for HALS volumes to reach 4,500tn in FY26, with realizations expected to improve to Rs495...

Clean Science (CLEAN)’s reported EBITDA in 2QFY25 was below our estimate at INR897m (+20% YoY), with a gross margin of 62.4% (vs. 65.9% in 2QFY24).

CLEAN’s R&D, focused on innovation and sustainability, achieved key milestones in FY24, including the commercialization of HALS series and the development of pharma intermediates.

CLEAN’s reported EBITDA in 1QFY25 was below our estimate at INR947m (+24% YoY), with a gross margin of 65.4%.

Clean Science’s Q4FY24 EBITDA dipped 10% YoY to INR 945mn; EBITDA margin contracted 295bp QoQ at 41.5%. EBITDA margin delivery has been impressive, considering pricing environment remains unfavourable.